Monday, November 9 2020
TherapeuticsMD Inc. (TXMD)
Q3 EPS: Annovera Sales Impress
TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The Company is committed to advancing the health of women and championing awareness of their healthcare issues.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Q3 2020 earnings release. The company reported third-quarter earnings today. Total revenues from marketed products were $19.3 mm and EPS was ($0.12), beating Street’s and our estimates of ($0.13) and ($0.13) in EPS and $15.5mm and $15.0 mm in revenues, respectively. TXMD shares gained approximately 30% in value (as of 2 pm ET) following the earnings release.
Annovera is the major revenue generator. The company achieved a record quarter for Annovera despite significantly reduced access to prescribers due to coronavirus. In Q3 2020, Annovera net sales were $6.4 mm. Total prescription (TRx) increased ~115%, while repeat writers doubled their average volume quarter over quarter (Q/Q). The company gained preferred coverage for Annovera with one of the top…
Click to get the full report
This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in the full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.